Emirates Oncology Society – EOS shared on LinkedIn:
Breaking News: HARMONi-GI1 Trial | ESMO 2026 | Emirates Oncology Society
Produced by Conveners.
Live from Madrid, Dr. Hala Abdellatif shares key findings from the Phase III HARMONi-GI1 trial, highlighting a promising advance in the treatment of advanced biliary tract cancer.
The trial demonstrated improved overall and progression-free survival with ivonescimab plus gemcitabine and cisplatin, extending median overall survival to 14.9 months versus 12.1 months with durvalumab plus chemotherapy, alongside higher response rates.
These findings highlight the potential of PD-1/VEGF-targeted therapy in advancing treatment options for patients with advanced biliary tract cancer.
Drop your questions in the comments, and stay tuned for more live updates from ESMO 2026!”
Proceed to the video attached to the post.
You can also read: HARMONi-GI1 at ESMO 2026: Ivonescimab Plus Chemotherapy in Advanced Biliary Tract Cancer
